Congress Should Open CBD Door, Close VMS Market Holes – Sharfstein, Cohen

Solutions to the US Food and Drug Administration's separate, but related problems with cannabinoids used as dietary ingredients and with the dietary supplement industry's regulatory compliance should come in the same legislation, suggest former senior agency official Joshua Sharfstein and public health researcher Pieter Cohen.

Meanwhile, an executive with a pharma firm marketing the only cannabis-derived ingredient approved by the FDA says the agency should reign in the "unfettered" production and sales of food and supplements containing cannabidiol, hemp or other cannabis-based substances to prevent potential harm to consumers